Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Evaluation of Exosomal Mir-155, Let-7G and Let-7I Levels As a Potential Noninvasive Biomarker Among Refractory/Relapsed Patients, Responsive Patients and Patients Receiving R-Chop Publisher Pubmed



Zare N1 ; Haghjooy Javanmard S2 ; Mehrzad V3 ; Eskandari N4 ; Kefayat A5
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Immunology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
  2. 2. Department of Physiology, School of Medicine and Applied Physiology Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran
  3. 3. Department of Hematology and Medical Oncology, Isfahan University of Medical Sciences, Isfahan, Iran
  4. 4. Department of Immunology, School of Medicine and Applied Physiology Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran
  5. 5. Cancer Prevention Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

Source: Leukemia and Lymphoma Published:2019


Abstract

This study aimed to investigate and compare exosomal miR-155, let-7g and let-7i levels as a noninvasive biomarker among patients with refractory/relapsed or responsive DLBCL after R-CHOP treatment and patients receiving R-CHOP. Plasma was collected and exosomes were isolated from plasma. Exosomes confirmed by zeta-seizer, electron microscope, and western blot. Exosomes concentration was investigated by BCA assay. MiR-155, let-7g and let-7i levels were evaluated in plasma-derived exosomes by real-time PCR. Plasma IFN-γ and IL-4 level were measured by ELISA assay. We observed the significant increase in the exosomal miR-155 levels (p =.002) and exosomes concentration (p =.001) in refractory/relapsed patients compared to responsive patients and patients receiving R-CHOP. No association was not observed between exosomal miR-155 levels and IPI and disease stage. The significant decrease in IFN-γ levels was observed in patients receiving R-CHOP compared to refractory/relapsed or responsive patients (p=.001). Therefore, exosomal miR-155 might be useful as potential prognostic biomarkers to predict response to treatment in DLBCL patients. © 2019, © 2019 Informa UK Limited, trading as Taylor & Francis Group.
Related Docs
View other Related Docs
1. The Expression Level of Hsa-Mir-146A-5P in Plasma-Derived Exosomes of Patients With Diffuse Large B-Cell Lymphoma, Journal of Research in Medical Sciences (2019)
2. Circulating Exosomes and Exosomal Micrornas As Biomarkers in Gastrointestinal Cancer, Cancer Gene Therapy (2017)
3. Exosomal Mirnas As Novel Cancer Biomarkers: Challenges and Opportunities, Journal of Cellular Physiology (2018)
4. Circulating Micrornas in Hepatocellular Carcinoma: Potential Diagnostic and Prognostic Biomarkers, Current Pharmaceutical Design (2016)
5. Effect of Plasma-Derived Exosomes of Refractory/Relapsed or Responsive Patients With Diffuse Large B-Cell Lymphoma on Natural Killer Cells Functions, Cell Journal (2020)
6. Gastrointestinal Cancer Drug Resistance: The Role of Exosomal Mirnas, Molecular Biology Reports (2022)
7. Epigenetic Regulation in Myocardial Infarction: Non-Coding Rnas and Exosomal Non-Coding Rnas, Frontiers in Cardiovascular Medicine (2022)
8. The Potential for Circulating Micrornas in the Diagnosis of Myocardial Infarction: A Novel Approach to Disease Diagnosis and Treatment, Current Pharmaceutical Design (2016)
Experts (# of related papers)
View all Related Experts
Nahid Eskandari (6)
Mohammadreza Sharifi (5)
Other Related Docs
9. Comparison of the Expression of Mir-326 Between Interferon Beta Responders and Non-Responders in Relapsing-Remitting Multiple Sclerosis, Cell Journal (2020)
10. Mir-145 and Mir20a-5P Potentially Mediate Pleiotropic Effects of Interferon-Beta Through Mitogen-Activated Protein Kinase Signaling Pathway in Multiple Sclerosis Patients, Journal of Molecular Neuroscience (2017)
11. Microrna-100 Shuttled by Mesenchymal Stem Cell-Derived Exosomes Suppresses in Vitro Angiogenesis Through Modulating the Mtor/Hif-1Α/Vegf Signaling Axis in Breast Cancer Cells, Cellular Oncology (2017)
12. Exosomal Noncoding Rnas in Prostate Cancer, Clinica Chimica Acta (2022)
13. The Effect of Interferon-Beta Therapy on T-Helper 17/Mir-326 and T-Helper 1/Mir-29B-3P Axis in Relapsing-Remitting Multiple Sclerosis Patients, NeuroImmunoModulation (2022)
14. Exploring the Role of Exosomes in Diabetic Neuropathy: From Molecular Mechanisms to Therapeutic Potential, Biomedicine and Pharmacotherapy (2025)
15. A Systematic Review of Extracellular Vesicles As Non-Invasive Biomarkers in Glioma Diagnosis, Prognosis, and Treatment Response Monitoring, Molecular Biology Reports (2021)
16. Connection of Mir-185 and Mir-320A Expression Levels With Response to Interferon-Beta in Multiple Sclerosis Patients, Multiple Sclerosis and Related Disorders (2020)
17. Microrna-155 and Exosomal Microrna-155: Small Pieces in the Cardiovascular Diseases Puzzle, Pathology Research and Practice (2024)
18. Microrna: Relevance to Stroke Diagnosis, Prognosis, and Therapy, Journal of Cellular Physiology (2018)
19. Micrornas As the Actors in the Atherosclerosis Scenario, Journal of Physiology and Biochemistry (2020)
20. Stem Cell-Derived Exosomes As Treatment for Stroke: A Systematic Review, Stem Cell Reviews and Reports (2021)
21. Emerging Role of Mesenchymal Stem/Stromal Cells (Mscs) and Mscs-Derived Exosomes in Bone- and Joint-Associated Musculoskeletal Disorders: A New Frontier, European Journal of Medical Research (2023)
22. Identification of Potential Biomarkers in the Peripheral Blood Mononuclear Cells of Relapsing–Remitting Multiple Sclerosis Patients, Inflammation (2022)
23. Chronic Obstructive Pulmonary Disease: Micrornas and Exosomes As New Diagnostic and Therapeutic Biomarkers, Journal of Research in Medical Sciences (2018)
24. Exosomes and Micrornas: New Potential Therapeutic Candidates in Alzheimer Disease Therapy, Journal of Cellular Physiology (2019)
25. Microrna: A Novel Target of Curcumin in Cancer Therapy, Journal of Cellular Physiology (2018)
26. State of the Art in Microrna As Diagnostic and Therapeutic Biomarkers in Chronic Lymphocytic Leukemia, Journal of Cellular Physiology (2018)
27. Micrornas in Retinoblastoma: Potential Diagnostic and Therapeutic Biomarkers, Journal of Cellular Physiology (2018)
28. The Role of Micrornas Involved in the Disorder of Blood–Brain Barrier in the Pathogenesis of Multiple Sclerosis, Frontiers in Immunology (2023)
29. Exosomes As Therapeutic and Drug Delivery Vehicle for Neurodegenerative Diseases, Journal of Nanobiotechnology (2024)
30. Therapeutic Potential of Mesenchymal Stem Cell-Derived Exosomes As a Cell-Free Therapy Approach for the Treatment of Skin, Bone, and Cartilage Defects, Connective Tissue Research (2022)
31. Comparison of Expression Levels of Mir-29B-3P and Mir-326 in T Helper-1 and T Helper-17 Cells Isolated From Responsive and Non-Responsive Relapsing-Remitting Multiple Sclerosis Patients Treated With Interferon-Beta, Iranian Journal of Allergy, Asthma and Immunology (2020)
32. Mir-504 Expression Level Is Increased in Multiple Sclerosis Patients Responder to Interferon-Beta, Journal of Neuroimmunology (2020)
33. Safety of Intraparenchymal Injection of Allogenic Placenta Mesenchymal Stem Cells Derived Exosome in Patients Undergoing Decompressive Craniectomy Following Malignant Middle Cerebral Artery Infarct, a Pilot Randomized Clinical Trial, International Journal of Preventive Medicine (2022)
34. Mesenchymal Stem/Stromal (Mscs)-Derived Exosome Inhibits Retinoblastoma Y-79 Cell Line Proliferation and Induces Their Apoptosis, Nanomedicine Research Journal (2022)
35. Mir-141 and Mir-200A, Revelation of New Possible Players in Modulation of Th17/Treg Differentiation and Pathogenesis of Multiple Sclerosis, PLoS ONE (2015)
36. Inducing Cell Proliferative Prevention in Human Acute Promyelocytic Leukemia by Mir-182 Inhibition Through Modulation of Casp9 Expression, Biomedicine and Pharmacotherapy (2017)
37. Glioblastoma: Exosome and Microrna As Novel Diagnosis Biomarkers, Cancer Gene Therapy (2016)
38. Hypoxia-Preconditioned Wj-Msc Spheroid-Derived Exosomes Delivering Mir-210 for Renal Cell Restoration in Hypoxia-Reoxygenation Injury, Stem Cell Research and Therapy (2024)
39. Micrornas: Key Modulators of Disease-Modifying Therapies in Multiple Sclerosis : Pancreatic Cancer Is One of the Lethal Malignant Tumours in the World.In This Study, We Investigated the Car T-Cell Therapy of Pancreatic Cancer, International Reviews of Immunology (2020)
40. Mir-326 and Mir-26A, Two Potential Markers for Diagnosis of Relapse and Remission Phases in Patient With Relapsing-Remitting Multiple Sclerosis, Gene (2014)
41. Stem Cell-Derived Nano-Scale Vesicles Promotes the Proliferation of Retinal Ganglion Cells (Rgcs) by Activation Pi3k/Akt and Erk Pathway, Nanomedicine Research Journal (2022)
42. The Effect of Beta Interferon on the Expression of Mir-145 in Patients With Multiple Sclerosis, Journal of Isfahan Medical School (2016)
43. Host and Pathogen-Directed Therapies Against Microbial Infections Using Exosome- and Antimicrobial Peptide-Derived Stem Cells With a Special Look at Pulmonary Infections and Sepsis, Stem Cell Reviews and Reports (2023)
44. Differential Expression Profile of Mir-27B, Mir-29A, and Mir-155 in Chronic Lymphocytic Leukemia and Breast Cancer Patients, Molecular Therapy Oncolytics (2020)
45. Exosomes and Non-Coding Rnas: Exploring Their Roles in Human Myocardial Dysfunction, Biomedicine and Pharmacotherapy (2025)